Imugene Limited (ASX: IMU)
One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease.
To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures.
One $30 million capped ASX junior may have a unique solution.
This ASX stock is attempting to develop cancer treatment drug that could be first in class, cost effective and has a unique difference.
The company is working in the immunotherapy space, an area touted as ‘a breakthrough’ treatment set to ‘revolutionise’ the oncological industry.
The immunotherapy space has attracted billion dollar Big Pharma deals. In fact, 20% of the top 10 Big Pharma deals in 2015 were in this space.
By developing its unique treatment, this company is not only looking to help cancer sufferers, but it could commercialise its drug, if it can attract Big Pharma dollars.
This is in a field where the average total deal size is $514.6 million – many times this company’s current $30 million market cap.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
At the helm of this tightly held company are two veterans of the industry who have already been involved in billion dollar deals.
With cash in the bank, the potential development of a unique treatment that could have a major positive affect on cancer management, and plenty of newsflow to come from its imminent trials, 2017 promises to be a busy and potentially very successful year for this company.